BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 36304466)

  • 1. Characterization of immune features and immunotherapy response in subtypes of hepatocellular carcinoma based on mitophagy.
    Wang Y; Peng B; Ning C; He S; Yang H; Mao Y; Sun L
    Front Immunol; 2022; 13():966167. PubMed ID: 36304466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Mitophagy-Related Gene Signature for Subtype Identification and Prognosis Prediction of Hepatocellular Carcinoma.
    Liu C; Wu Z; Wang L; Yang Q; Huang J; Huang J
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36292980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma.
    Zhu J; Huang Q; Peng X; Luo C; Liu Z; Liu D; Yuan H; Yuan R; Cheng X
    Front Immunol; 2023; 14():1218661. PubMed ID: 37662906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An immune-related gene signature for predicting survival and immunotherapy efficacy in hepatocellular carcinoma.
    Dai Y; Qiang W; Lin K; Gui Y; Lan X; Wang D
    Cancer Immunol Immunother; 2021 Apr; 70(4):967-979. PubMed ID: 33089373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Molecular Analyses of a Macrophage-Related Gene Signature With Regard to Prognosis, Immune Features, and Biomarkers for Immunotherapy in Hepatocellular Carcinoma Based on WGCNA and the LASSO Algorithm.
    Wang T; Dai L; Shen S; Yang Y; Yang M; Yang X; Qiu Y; Wang W
    Front Immunol; 2022; 13():843408. PubMed ID: 35693827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma.
    Wang Y; Song F; Zhang X; Yang C
    Oxid Med Cell Longev; 2022; 2022():1592905. PubMed ID: 35535359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
    Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
    BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Ferroptosis-related molecular model and immune subtypes of hepatocellular carcinoma for individual therapy.
    Long S; Chen Y; Wang Y; Yao Y; Xiao S; Fu K
    Cancer Med; 2023 Jan; 12(2):2134-2147. PubMed ID: 35841206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An immune-related signature for optimizing prognosis prediction and treatment decision of hepatocellular carcinoma.
    Yao N; Jiang W; Wang Y; Song Q; Cao X; Zheng W; Zhang J
    Eur J Med Res; 2023 Mar; 28(1):123. PubMed ID: 36918943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential biomarkers for the prognosis and treatment of HCC immunotherapy.
    Li H; He Q; Zhou GM; Wang WJ; Shi PP; Wang ZH
    Eur Rev Med Pharmacol Sci; 2023 Mar; 27(5):2027-2046. PubMed ID: 36930502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of chromatin organization-related gene signature for hepatocellular carcinoma prognosis and predicting immunotherapy response.
    Chen J; Chen X; Li T; Wang L; Lin G
    Int Immunopharmacol; 2022 Aug; 109():108866. PubMed ID: 35691273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Unfolded Protein Response-Related mRNA Signature Predicting the Survival and Therapeutic Effect of Hepatocellular Carcinoma.
    Su Z; Wang L; Chen X; Zhong X; Wang D; Wang J; Shao L; Chen G; Wu J
    Comb Chem High Throughput Screen; 2022; 25(12):2046-2058. PubMed ID: 35125080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
    Luo Y; Liu H; Fu H; Ding GS; Teng F
    Front Immunol; 2022; 13():974377. PubMed ID: 36458010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Model based on five tumour immune microenvironment-related genes for predicting hepatocellular carcinoma immunotherapy outcomes.
    Gu X; Guan J; Xu J; Zheng Q; Chen C; Yang Q; Huang C; Wang G; Zhou H; Chen Z; Zhu H
    J Transl Med; 2021 Jan; 19(1):26. PubMed ID: 33407546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
    Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
    Front Genet; 2022; 13():919389. PubMed ID: 35783281
    [No Abstract]   [Full Text] [Related]  

  • 16. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
    Li L; Xie R; Lu G
    Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and validation of a fatty acid metabolism-related lncRNA signature as a predictor for prognosis and immunotherapy in patients with liver cancer.
    Chen E; Yi J; Jiang J; Zou Z; Mo Y; Ren Q; Lin Z; Lu Y; Zhang J; Liu J
    BMC Cancer; 2022 Oct; 22(1):1037. PubMed ID: 36195833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Four-gene signature predicting overall survival and immune infiltration in hepatocellular carcinoma by bioinformatics analysis with RT‒qPCR validation.
    Guan R; Zou J; Mei J; Deng M; Guo R
    BMC Cancer; 2022 Jul; 22(1):830. PubMed ID: 35907846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and validation of a novel immune-related prognostic model in hepatocellular carcinoma.
    Wang Z; Zhu J; Liu Y; Liu C; Wang W; Chen F; Ma L
    J Transl Med; 2020 Feb; 18(1):67. PubMed ID: 32046766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma.
    Chen Y; Wang X; Deng X; Zhang Y; Liao R; Li Y; Yang H; Chen K
    Front Immunol; 2021; 12():676922. PubMed ID: 34335575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.